Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
KENILWORTH, N.J.–(BUSINESS WIRE)–July 24, 2018 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced […]